- Details
- Vadim Koshkin discusses a phase II study of combination therapy using futibatinib and pembrolizumab in advanced metastatic urothelial cancer. The study explores two patient cohorts: those with FGFR3 mutations or FGFR fusions, and those without these biomarkers. The results show promising anti-tumor activity, particularly in the biomarker-defined cohort, with encouraging response rates and survival...
|
- Details
- Deepak Kilari joins Zach Klaassen to discuss the ORACLE study examining outcomes with novel combination therapies in non-clear cell renal cell carcinoma (RCC). The multicenter retrospective study analyzes 253 patients across major academic centers, investigating different treatment combinations including IO+IO, IO+VEGF, and VEGF+mTOR therapies across various non-clear cell RCC subtypes. The resear...
|
- Details
- Alicia Morgans speaks with Jonathan Rosenberg about two novel therapies presented at ESMO 2024. The discussion centers on BL-B01D1, a bispecific antibody-drug conjugate targeting EGFR and HER3 in advanced urothelial cancer, which shows promising early results with a 40% response rate in previously treated patients. The conversation also explores NKT2152, a HIF2a inhibitor for renal cell carcinoma,...
|
- Details
- Ursula Vogl discusses key prostate cancer highlights from ESMO 2024. The conversation explores three major trials across different disease stages: the PATCH trial evaluating transdermal estradiol versus LHRH analogs in non-metastatic disease, the ARANOTE trial examining darolutamide in metastatic hormone-sensitive prostate cancer, and the PEACE-3 trial investigating radium-223 plus enzalutamide in...
|
- Details
- Alicia Morgans hosts Jonathan Rosenberg to discuss the five-year outcomes from EV-103 Cohort A, examining enfortumab vedotin plus pembrolizumab in cisplatin-ineligible advanced urothelial cancer patients. The conversation highlights unprecedented long-term results, with over 40% of patients alive at five years—a dramatic improvement from historical survival rates of approximately 3% with tradition...
|
- Details
- Thomas Powles joins Zachary Klaassen to discuss the NIAGARA trial results. The phase III study examines the addition of durvalumab to cisplatin-based chemotherapy in the perioperative setting for muscle-invasive bladder cancer, representing the largest trial in this space with 1,000 patients. The conversation highlights significant improvements in event-free survival, pathological complete respons...
|
- Details
- Thomas Powles discusses an exploratory nectin-4 biomarker analysis from the EV-302 trial. The conversation examines the role of nectin-4 expression in enfortumab vedotin plus pembrolizumab (EV-Pembro) therapy for bladder cancer, highlighting consistent benefits across expression levels compared to chemotherapy. While over 90% of patients express high levels of nectin-4, the discussion emphasizes t...
|
- Details
- Wilbert Zwart joins Neeraj Agarwal to discuss research on epigenetic targeting in prostate cancer. The discussion examines histone markers in metastatic castration-resistant prostate cancer (mCRPC) patients to predict response to enzalutamide treatment. Using patient-derived xenografts and computational modeling, the research identifies HDAC3 as a key target and demonstrates synergistic effects wh...
|
- Details
- Laurence Albiges joins Zachary Klaassen to discuss the CheckMate 67T trial results. The phase 3 non-inferiority study compares subcutaneous versus intravenous administration of nivolumab in renal cell carcinoma patients who have failed prior VEGF-TKI therapy. The trial meets its co-primary pharmacokinetic endpoints, demonstrating non-inferiority of subcutaneous administration, while showing simila...
|
- Details
- Brian Rini joins Pedro Barata to discuss the updated results of the Phase 3 LITESPARK-005 trial. The study, which led to belzutifan's approval in December 2023, compares belzutifan to everolimus in refractory clear cell RCC patients who previously received PD-1/PD-L1 and VEGF-TKI therapy. While the trial demonstrates improved progression-free survival and response rates with belzutifan, overall su...
|
